Table 2.
Multivariable analysis of OS and PFS for patients with all stages, early-stage, and advanced-stage disease
| Variables | OS | PFS | ||
|---|---|---|---|---|
| HR (95% CI) | P | HR (95% CI) | P | |
| All stages (n = 2560) | ||||
| Year of treatment | ||||
| 2000-2004 | Reference | Reference | ||
| 2005-2009 | 0.99 (0.81-1.21) | .889 | 1.09 (0.91-1.30) | .343 |
| 2010-2015 | 0.87 (0.70-1.09) | .220 | 0.97 (0.80-1.18) | .763 |
| Sex (female vs male) | 0.91 (0.78-1.06) | .216 | 0.93 (0.80-1.06) | .287 |
| Age (>60 y vs ≤60 y) | 1.61 (1.33-1.95) | <.001 | 1.34 (1.13-1.59) | .001 |
| B symptoms (yes vs no) | 1.01 (0.88-1.17) | .873 | 1.06 (0.94-1.20) | .365 |
| ECOG score (≥2 vs 0-1) | 2.15 (1.76-2.62) | <.001 | 1.80 (1.50-2.17) | <.001 |
| Ann Arbor stage (III-IV vs I-II) | 2.26 (1.77-2.89) | <.001 | 1.96 (1.57-2.45) | <.001 |
| Elevated LDH (yes vs no) | 1.39 (1.20-1.60) | <.001 | 1.17 (1.03-1.32) | .017 |
| PTI (yes vs no) | 1.58 (1.37-1.83) | <.001 | 1.50 (1.33-1.70) | <.001 |
| UADT site (yes vs no) | 1.00 (0.76-1.31) | .987 | 0.90 (0.71-1.14) | .386 |
| Regional LN involvement (yes vs no) | 1.40 (1.21-1.62) | <.001 | 1.25 (1.10-1.42) | <.001 |
| Distant LN involvement (yes vs no) | 1.77 (1.30-2.39) | <.001 | 1.78 (1.35-2.35) | <.001 |
| Radiotherapy (yes vs no) | 0.42 (0.35-0.49) | <.001 | 0.38 (0.33-0.44) | <.001 |
| Regimen (non-ANT vs ANT based) | 0.72 (0.60-0.85) | <.001 | 0.63 (0.54-0.73) | <.001 |
| Stage I-II (n = 2226) | ||||
| Year of treatment | ||||
| 2000-2004 | Reference | Reference | ||
| 2005-2009 | 0.93 (0.75-1.16) | .517 | 1.06 (0.88-1.29) | .519 |
| 2010-2015 | 0.76 (0.59-0.97) | .027 | 0.91 (0.74-1.13) | .401 |
| Sex (female vs male) | 0.85 (0.71-1.02) | .073 | 0.92 (0.79-1.06) | .252 |
| Age (>60 y vs ≤60 y) | 1.54 (1.25-1.91) | <.001 | 1.32 (1.10-1.59) | .004 |
| B symptoms (yes vs no) | 0.99 (0.85-1.16) | .918 | 1.09 (0.95-1.25) | .213 |
| ECOG score (≥2 vs 0-1) | 2.27 (1.77-2.91) | <.001 | 1.97 (1.57-2.47) | <.001 |
| Ann Arbor stage (II vs I) | 1.44 (1.23-1.70) | <.001 | 1.29 (1.13-1.49) | <.001 |
| Elevated LDH (yes vs no) | 1.25 (1.06-1.48) | .008 | 1.08 (0.93-1.24) | .315 |
| PTI (yes vs no) | 1.63 (1.37-1.93) | <.001 | 1.55 (1.35-1.79) | <.001 |
| UADT site (yes vs no) | 0.95 (0.59-1.55) | .843 | 1.24 (0.87-1.78) | .237 |
| Radiotherapy (yes vs no) | 0.43 (0.35-0.51) | <.001 | 0.37 (0.32-0.43) | <.001 |
| Regimen (non-ANT vs ANT based) | 0.79 (0.64-0.97) | .021 | 0.67 (0.56-0.79) | <.001 |
| Stage III-IV (n = 334) | ||||
| Year of treatment | ||||
| 2000-2004 | Reference | Reference | ||
| 2005-2009 | 1.44 (0.83-2.48) | .192 | 1.30 (0.78-2.14) | .312 |
| 2010-2015 | 1.67 (0.96-2.89) | .070 | 1.26 (0.76-2.09) | .371 |
| Sex (female vs male) | 1.02 (0.73-1.41) | .934 | 0.93 (0.69-1.25) | .619 |
| Age (>60 y vs ≤60 y) | 2.24 (1.44-3.48) | <.001 | 1.47 (0.96-2.27) | .079 |
| B symptoms (yes vs no) | 1.16 (0.86-1.58) | .334 | 0.98 (0.74-1.30) | .888 |
| ECOG score (≥2 vs 0-1) | 1.76 (1.26-2.47) | .001 | 1.53 (1.12-2.08) | .008 |
| Elevated LDH (yes vs no) | 1.97 (1.44-2.69) | <.001 | 1.59 (1.20-2.10) | .001 |
| PTI (yes vs no) | 1.42 (1.04-1.93) | .028 | 1.36 (1.02-1.80) | .036 |
| Distant LN involvement (yes vs no) | 0.69 (0.53-0.94) | .020 | 0.61 (0.46-0.82) | .001 |
| Radiotherapy (yes vs no) | 0.38 (0.26-0.54) | <.001 | 0.44 (0.32-0.60) | <.001 |
| Regimen (non-ANT vs ANT based) | 0.55 (0.38-0.78) | .001 | 0.54 (0.-0.75) | <.001 |